News

October 17, 2018October 17, 2018

Cosentyx Safe, Effective Through 5 Years of Treatment, Novartis Announces

News

Five-year treatment with Cosentyx (secukinumab) is safe and effective in easing signs and symptoms of ankylosing spondylitis (AS), according to results of a Phase 3 extension clinical trial. This new data are ... Read more

October 15, 2018October 15, 2018

Low Levels of Specific Immune Cell Linked to Ankylosing Spondylitis Manifestations, Mouse Study Suggests

News

Malfunction of the ankylosing spondylitis-associated gene, ERAP1, is connected to the loss of a certain type of immune cell, which seems to contribute to the inflammation process associated with the ... Read more

October 10, 2018October 10, 2018

Advocacy Groups, Doctors Question Rising Prices of Rare Disease Treatments

News

Half a year has gone by since disgraced pharma executive Martin Shkreli was sentenced to seven years in federal prison for securities and wire fraud while heading San Diego-based ... Read more

October 8, 2018October 8, 2018

Gender-specific Predictors of AS Spinal Radiographic Progression Identified in 5-Year Study

News

Risk factors of new spinal bone formation in patients with ankylosing spondylitis (AS) partially differ between men and women, according to a five-year Swedish study. The study, “A five-year ... Read more

October 3, 2018October 3, 2018

Humira Biosimilar, Hulio, Will Soon Be Available to AS, Other Patients in Europe

News

The European Commission (EU) has granted marketing authorization for Hulio, a biosimilar to Humira, for the treatment of a number of chronic inflammatory diseases including ankylosing spondylitis. According to the ... Read more

September 26, 2018September 26, 2018

Depression Prevalent in Axial Spondyloarthritis Patients, Linked to Disease Severity, Review Shows

News

Depression is prevalent among patients with axial spondyloarthritis and correlates with more severe disease activity, according to a detailed review of literature. The study, “The prevalence of depression in ... Read more

September 21, 2018

#NORDSummit – More Than 700 Expected to Attend Oct. 15-16 Rare Disease Summit in Washington

News

More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products ... Read more

September 19, 2018September 19, 2018

AS Linked to Impaired Small Blood Vessels, But Manageable with Certain Inhibitors

News

TNF-α inhibitors have the potential to prevent heart disease among patients with ankylosing spondylitis (AS) by improving blood flow in small blood vessels, researchers suggest. Their study, “Microvascular dysfunction in ... Read more

September 12, 2018September 12, 2018

Cardiovascular Fitness of Patients Linked to Risk of Heart Disease in Study

News

Poorer heart and lung function appears to be related to an increased risk of cardiovascular disease in people with ankylosing spondylitis, reported a study that suggested more aerobic exercises might ... Read more

September 10, 2018September 10, 2018

Filgotinib Seen to Reduce AS Disease Activity in Phase 2 Trial, Results Show

News

Filgotinib, an investigational therapy for ankylosing spondylitis, was able to significantly reduce disease activity, according to recent Phase 2 study results announced by Gilead Sciences and Galapagos biotech companies. The TORTUGA trial reached ... Read more

Pin It on Pinterest